JNJ Stock Price Today (September 2026) — Johnson & Johnson Analysis & Key Metrics 2026-09-04
Johnson & Johnson (JNJ) is trading at $275.23, down 1.15% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $272.50 (-1.0% upside).
- Volatility remains elevated (20.51% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.60% YoY) alongside significant competitive pressures.
JNJ Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Johnson & Johnson - Historical Price & Volume
Market Cap
Enterprise Value: $674.23B
P/E Ratio
Forward P/E: 21.60
Revenue Growth
Year over Year
Analyst Target
+-1.0% upside potential
Key Investor Questions About JNJ
What investors need to know before buying
Based on current market data, JNJ presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 62.15)
- Fundamentals say: Caution warranted (high leverage concerns)
JNJ's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for JNJ investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $49.04B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, JNJ stock traded between $173.33 and $276.47—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.51% annualized volatility and β=0.01, the stock exhibits low sensitivity to market moves—making JNJ suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
3 Dividend Kings Built to Keep Raising Your Income When Rates Rise
Treasury yields near a one-year high are punishing most dividend stocks, but a handful of Dividend Kings kept signing bigger checks every single quarter without missing a beat. The question is whether their balance sheets can keep that streak alive.
How Much Upside Can BSX Stock's Growth Deliver?
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.
Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.
Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's biggest drugs faces a brutal competitive hit.
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
Is Johnson & Johnson (JNJ) Cheap After The Louisiana Talc Verdict?
Johnson & Johnson (JNJ) is back in the spotlight after a Louisiana jury found the company liable in a talc related mesothelioma case, adding a fresh layer to its ongoing litigation risk. Against this backdrop, Johnson & Johnson’s recent 7 day share price return of 4.76% and 30 day share price return of 9.22% indicate that momentum has been building ahead of the Louisiana verdict and the latest FDA approval, while the 1 year total shareholder return of 59.27% and 5 year total shareholder...
J&J Gains as AbbVie Posts 74% Myeloma Response
Etentamig could expand treatment after CAR-T therapy without immediately displacing J&J's fast-growing Carvykti franchise.
Protolabs CEO sees big impact from US reshoring despite potential tariffs
Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.
Explore More Analysis for JNJ
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Johnson & Johnson
Johnson & Johnson (JNJ) is currently trading at $275.23. The RSI (14-day) is at 62.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $272.50 implies 1.0% downside from current levels. Volatility is moderate at 20.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Johnson & Johnson (JNJ): The trailing P/E ratio is 32.15, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 21.60, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 4.66, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 7.80. Price-to-Sales is 6.77. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering JNJ, the consensus price target is $272.50. This represents a 1.0% downside from the current price of $275.23. The range spans from a low target of $190.00 to a high target of $305.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Johnson & Johnson (JNJ) pays a dividend with a current yield of approximately 1.95%. The annualized dividend rate is $5.24 per share. The payout ratio is 60.8%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-08-25T00:00:00.000Z.
Key risks for Johnson & Johnson (JNJ) investors include: 1. Elevated short interest (100.0% of float) suggests significant bearish sentiment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Johnson & Johnson's (JNJ) current debt and financial health profile: Total debt stands at $49.04B. The debt-to-equity ratio is 57.71, which is moderate and generally manageable for most companies. The current ratio is 1.09, indicating adequate short-term liquidity. The quick ratio is 0.72. The company holds $20.76B in cash and equivalents. Free cash flow is positive at $16.89B, providing a cushion for debt servicing and shareholder returns.